SUBSCRIBE
SUBSCRIBE
News   FDA

Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial

May 23, 2008 | 
1 min read
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn-Strides, LLC today announced the approval of an ANDA for Rifampin for Injection USP, 600 mg/vial. This is the first lyophilized Injectable product approval for the Joint Venture.
FDA Approvals
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Human brain with abstract visualization of neuron activity
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
July 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
July 9, 2025
 · 
1 min read
 · 
Heather McKenzie
FDA signage at its headquarters in Maryland
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
 · 
3 min read
 · 
Heather McKenzie
Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.
Approvals
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
July 7, 2025
 · 
2 min read
 · 
Tristan Manalac